Swiss National Bank Acquires 31,900 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Swiss National Bank increased its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 13.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 274,000 shares of the company's stock after buying an additional 31,900 shares during the quarter. Swiss National Bank owned 0.09% of Amneal Pharmaceuticals worth $2,170,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Amneal Pharmaceuticals in the 4th quarter valued at $81,000. Quest Partners LLC bought a new stake in Amneal Pharmaceuticals in the third quarter valued at about $84,000. Janney Montgomery Scott LLC acquired a new position in Amneal Pharmaceuticals in the fourth quarter worth about $121,000. Quadrature Capital Ltd bought a new position in Amneal Pharmaceuticals during the third quarter worth about $169,000. Finally, Amundi acquired a new stake in Amneal Pharmaceuticals during the fourth quarter valued at approximately $256,000. 31.82% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of Amneal Pharmaceuticals stock in a transaction on Friday, March 14th. The stock was sold at an average price of $8.35, for a total value of $41,750,000.00. Following the completion of the sale, the insider now directly owns 48,578,209 shares of the company's stock, valued at approximately $405,628,045.15. This trade represents a 9.33 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gautam Patel sold 62,590 shares of the company's stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $8.01, for a total value of $501,345.90. Following the transaction, the director now directly owns 1,968,886 shares in the company, valued at $15,770,776.86. This trade represents a 3.08 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 5,240,000 shares of company stock worth $43,754,000. 26.56% of the stock is currently owned by corporate insiders.

Remove Ads

Amneal Pharmaceuticals Stock Up 1.2 %

AMRX stock traded up $0.10 during midday trading on Monday, reaching $8.38. 2,643,588 shares of the company's stock traded hands, compared to its average volume of 1,376,317. The company has a 50-day simple moving average of $8.42 and a two-hundred day simple moving average of $8.37. Amneal Pharmaceuticals, Inc. has a 1-year low of $5.18 and a 1-year high of $9.48. The company has a market cap of $2.60 billion, a price-to-earnings ratio of -12.32 and a beta of 1.05.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its earnings results on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The business had revenue of $730.52 million for the quarter, compared to the consensus estimate of $708.21 million. During the same quarter in the previous year, the company posted $0.14 EPS. Equities research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Barclays increased their target price on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a report on Monday, March 3rd. StockNews.com cut Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, December 19th. Finally, JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their target price for the company from $9.00 to $12.00 in a research note on Monday, February 24th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $10.80.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.